

## SUPPLEMENTARY INFORMATION

### Supplementary Figure S1: Newcastle-Ottawa quality assessment scale.

#### NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE COHORT STUDIES

Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability

##### Selection

- 1) Representativeness of the exposed cohort
  - a) truly representative of the average \_\_\_\_\_ (describe) in the community \*
  - b) somewhat representative of the average \_\_\_\_\_ in the community \*
  - c) selected group of users eg nurses, volunteers
  - d) no description of the derivation of the cohort
- 2) Selection of the non exposed cohort
  - a) drawn from the same community as the exposed cohort \*
  - b) drawn from a different source
  - c) no description of the derivation of the non exposed cohort
- 3) Ascertainment of exposure
  - a) secure record (eg surgical records) \*
  - b) structured interview \*
  - c) written self report
  - d) no description
- 4) Demonstration that outcome of interest was not present at start of study
  - a) yes \*
  - b) no

##### Comparability


- 1) Comparability of cohorts on the basis of the design or analysis
  - a) study controls for \_\_\_\_\_ (select the most important factor) \*
  - b) study controls for any additional factor \* (This criteria could be modified to indicate specific control for a second important factor.)

##### Outcome


- 1) Assessment of outcome
  - a) independent blind assessment \*
  - b) record linkage \*
  - c) self report
  - d) no description
- 2) Was follow-up long enough for outcomes to occur
  - a) yes (select an adequate follow up period for outcome of interest) \*
  - b) no
- 3) Adequacy of follow up of cohorts
  - a) complete follow up - all subjects accounted for \*
  - b) subjects lost to follow up unlikely to introduce bias - small number lost - > \_\_\_\_ % (select an adequate %) follow up, or description provided of those lost) \*
  - c) follow up rate < \_\_\_\_ % (select an adequate %) and no description of those lost
  - d) no statement

**Supplementary Figure S2. Corticosteroid free-clinical remission.**


(A)



(B)




(C)




(A) Corticosteroid free clinical remission in short-term (8w-14w), (B) Corticosteroid free clinical remission in medium-term (16w-24w), (C) Corticosteroid free clinical remission in long-term (48w-52w)

**Supplementary Figure S3. Endoscopic remission.**

(A)




(B)




(A) Endoscopic remission in medium-term (16w-24w), (B) Endoscopic remission in long-term (48w-52w).

**Supplementary Figure S4: Publication bias.**


**(A) Clinical response short-term**




**(B) Clinical remission short-term**




### (C) Corticosteroid-free clinical remission short-term




### (D) Clinical response medium-term




### (E) Clinical remission medium-term




### (F) Corticosteroid-free clinical remission medium-term



### (G) Endoscopic remission medium-term




### (H) Clinical response long-term






### (I) Clinical remission long-term



### (J) Corticosteroid-free clinical remission long-term



(K) Endoscopic remission long-term

